Stay updated on Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedMajor update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.SummaryDifference3%
- Check24 days agoChange DetectedRemoved several Neoplasms and Carcinoma-related terms and added a new version identifier v3.1.0. The page now presents fewer taxonomic categories and indicates the updated version.SummaryDifference0.7%
- Check39 days agoChange DetectedRevision: v3.0.2 is now shown, replacing v3.0.1; the Back to Top control was removed.SummaryDifference0.2%
- Check46 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check53 days agoChange DetectedThe web page has added significant medical terminology related to ovarian and female urogenital diseases, as well as the facility name and location, while removing various related resources and terms.SummaryDifference5%
- Check68 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.